CERo Therapeutics Holdings, Inc. announced the successful completion of toxicology studies for its lead compound, CER-1236.  The toxicology studies will be included in the Investigational New Drug Application (IND) package the Company plans to send to the U.S. Food and Drug Administration (FDA) in order to receive clearance to begin human trials (Phase1) with the compound. With these toxicology studies complete and in the Company?s judgment determined to be IND-enabling, CERo is now focusing on ensuring compliant manufacturing procedures and practices, which are among the final IND-enabling studies the Company must complete ahead of the IND submission.